France Wrote to Thousands of Women on the Pill: Not a Batch Recall or Shortage Trigger

Receiving an official letter signed by a health agency always sends a chill down your spine. Yet, contrary to what one might imagine, this letter slipped into thousands of mailboxes in recent days does not announce a drug recall nor a stock shortage. It has nothing to do with a major health scandal either. It is a much subtler and, above all, more reassuring approach than it first appears, centered on a topic long kept discreet: the link between certain hormonal contraceptives and a rare risk of meningioma. This raises legitimate questions among the women concerned, caught between worry and confusion.

This letter that sows doubt: what does the ANSM really say?

Everything starts with a study conducted by EPI-PHARE, an organization specialized in the study of medicines on a large scale. Its work highlighted a very small increase in the risk of meningioma among women using a desogestrel-based contraception over an extended period, that is to say for at least one year. This information was sufficiently serious for the European Medicines Agency to request, in July 2026, the addition of this note to the label of the affected contraceptives. Rather than waiting for a discreet update of the leaflet slipped into the box, the ANSM chose, in September 2026, to go further: to inform directly, by personalized letter, the women using this type of pill as well as the health professionals who prescribed it. This openness explains the document’s somewhat solemn tone.

Receiving this letter does not mean you are ill

First and perhaps most importantly: this letter is neither a diagnosis nor a medical emergency. It is primarily a preventive and informational step designed so that every affected woman has the same information as her physician. The ANSM clearly reiterates in its communication: do not stop your contraception on your own after reading the letter. A sudden stop, taken alone in a moment of panic, would expose you to a much more immediate and tangible risk, that of an unwanted pregnancy. In other words, spontaneous relief could prove more problematic than the risk mentioned in the letter itself. This kind of reaction, as understandable as it may be when faced with a word like meningioma, deserves to be tempered with a little perspective.

What to do in reality: engage in dialogue, not panic

So, what concrete stance should one take when removing this letter from the envelope? The answer comes down to one word: dialogue. The ANSM invites the women concerned to talk with their doctor or midwife, to evaluate their individual situation, without haste or routine testing. And that is where a crucial nuance lies: the agency does not recommend systematic MRI scans for all desogestrel users. It is therefore not a matter of rushing toward an imaging test as soon as the letter is read, but rather of opening a discussion tailored to each person’s journey, each medical history, and each question. This approach fits into a broader policy of monitoring progestogens conducted by the ANSM, which has been carrying out this type of information campaigns for several years. The stated goal remains the same: to empower each person to remain in charge of their health, rather than seeking answers on the internet alone, often anxiety-inducing and rarely suited to an individual’s personal situation.

In essence, this letter resembles less of a red alert and more of an invitation to shared vigilance. The risk mentioned remains rare, contraception remains an essential tool, and the best compass, as is often the case, is a conversation with a trusted health professional. A simple question remains, but far from trivial: what if this transparency, as destabilizing as it might be in the moment, becomes the new standard for all everyday medications?